 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C27H24F3NO |
| Molar mass | 435.490 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JWH-363 (1-Naphthyl{1-pentyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanone) is asynthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of theCB1 (Ki = 245 ± 5nM) andCB2 (Ki = 71 ± 1nM) receptors, with a moderate (~3.45x) selectivity for the latter. JWH-363 was first synthesized in 2006 byJohn W. Huffman and colleagues to examine the nature of ligand binding to theCB1 receptor.[1]
In the United States JWH-363 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-363.[2][3][4][5]
In Canada, JWH-363 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under theControlled Drugs and Substances Act.
In the United Kingdom, JWH-363 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under theMisuse of Drugs Act 1971.
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
